QUÉBEC CITY, July 6, 2019 /CNW/ - A notice of authorization of a class action regarding the oral contraceptives Yasmin and/or Yaz is published today. This class action against the defendant Bayer inc. is based on allegations regarding alleged increased risks of arterial thrombosis, pulmonary embolism, venous thromboembolism or gallbladder disease associated with the use of Yasmin and/or Yaz compared to other oral contraceptives, as well as allegations of insufficiency of the warning to the members of the Class and/or their physicians regarding these alleged increased risks, and of alleged misleading representations regarding the safe nature of the oral contraceptives Yasmin and/or Yaz.
The class action seeks to obtain monetary damages from the defendant in order to compensate the Class members for the bodily, material and moral damages suffered, allegedly resulting from the use of Yasmin and/or Yaz. The court has not yet decided whether the defendant has committed a fault and the defendant is contesting the class action.
The class action includes all persons residing in Québec, who were prescribed and ingested the drugs Yasmin and/or Yaz, from their respective introduction into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of Yaz) and the date of November 30, 2011, and who were diagnosed with deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease, and their successors, assigns, family members, and dependants (the "Class").
Class members who do not want to be part of the class action have to opt-out before September 4, 2019. The Opt-Out Form and more information are available at https://www.siskinds.com/class-action/yasmin-yaz/.
Contact information for Class members:
For telephone inquiries, please call (418) 694-2009.
Contact information for media:
Siskinds, Desmeules, Avocats, s.e.n.c.r.l.
SOURCE Siskinds LLP